Reaction
Injection Site Indentation reporting signals
As of the last recalculation, Injection Site Indentation appears in 2,012 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is ERENUMAB-AOOE (PRR 36.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Erenumab-Aooe | 177 | 36.3 | 36.5 |
| Alirocumab | 84 | 36.1 | 36.2 |
| Glatiramer Acetate | 136 | 25.2 | 25.2 |
| Evolocumab | 300 | 22.3 | 22.4 |
| Asfotase Alfa | 19 | 19.8 | 19.8 |
| Cabotegravir | 11 | 14.2 | 14.2 |
| Peginterferon Beta-1A | 17 | 13.5 | 13.5 |
| Botulinum Toxin Type A | 14 | 11.7 | 11.8 |
| Fremanezumab-Vfrm | 12 | 10.9 | 10.9 |
| Benralizumab | 19 | 9.9 | 9.9 |
| Triamcinolone Acetonide | 20 | 6.8 | 6.8 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 15 | 6.7 | 6.7 |
| Tirzepatide | 80 | 5.3 | 5.3 |
| Dulaglutide | 42 | 5.0 | 5.0 |
| Onabotulinumtoxina | 34 | 4.6 | 4.6 |
| Oral Semaglutide | 30 | 4.3 | 4.3 |
| Naltrexone | 12 | 4.0 | 4.0 |
| Galcanezumab-Gnlm | 11 | 3.6 | 3.6 |
| Nemolizumab-Ilto | 4 | 3.3 | 3.3 |
| Abaloparatide | 9 | 3.2 | 3.2 |
| Exenatide | 13 | 2.6 | 2.6 |
| Dupilumab | 69 | 1.5 | 1.5 |